SAVED
File name .JPG
File alt. text
Image should be px wide x px tall.
Select Image
home - Pancreas - Pancreatic Cancers - VIPoma Written by Dr Sebastian Zeki
Knowledge


Knows the presentation investigation and staging of pancreatic
cancer

Recognises the importance of considering and being able to identify
uncommon pancreatic tumours (such as neuroendocrine or
intrapapillary mucinous tuours)

Knows the range of potential therapies and recognises the factors
that make such tumours potentially operable or inoperable

Knows the prevalence and natural history of benign cysts/serous
cystadenoma and potentially malignant cystic lesions

Knows the options for palliative treatment
Skills
Shows ability to sequence investigations appropriately
Understands value of multi-disciplinary team
Recognises the importance of considering possibility that the tumour
is unusual

Behaviours
Communicates effectively within the multi-disciplinary team and with
the patient and their family

VIPoma

>3cm diameter Luminal epithelium Inc cAMP productionNet fluid secretion into lumen VIPoma Diagnosis[Serum VIP] > 75 pg/mL (measured by radioimmu-noassay.) ; repeat if elevated. CT/ Octreotide scan/ EUS can help locate the lesion. VIP SYndrome (pancreatic cholera syndrome, Verner-Morrison syndrome)=watery diarrhea, hypokalemia, and hypochlorhydria or achlorhydria (WDHA) syndrome20% get facial flushing VIP secreted Lesion characteristicsLesions are solitaryThey are usually >3cm .They are usually in the tail.They usually have metastasized by dx.They can occur outside the pancreas. Prognosis The 5 year survival is 88%. Incidence of 1/10,000,000 Written by Dr Sebastian Zeki

Related Stories

•Neuroendocrine Tumors of the Gallbladder: A Multicenter Case Series and Systematic Literature Review Indicating Predominantly Non-Aggressive Tumor Behavior and a Common Association with Cholesterol Polyps and Cholesterolosis

•Association between non-high-density lipoprotein cholesterol and high-risk intraductal papillary mucinous neoplasm

•BRCA1/2 Reversion Mutations and Cancer Therapy Resistance

•Stakeholder Consensus Selection of Data Elements and Indicators for a Pancreatic Cancer Surgical Outcomes Registry in Australia and Aotearoa New Zealand: Modified Delphi Process

•Potential mechanisms underlying Enterococcus faecalis-driven pancreatic cancer cell proliferation